Key business with prescription medicines continues to boost growth at Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim

New Spiriva® Respimat® inhaler completes European approval process for COPD
- Details
- Category: Boehringer Ingelheim

Boehringer Ingelheim announces first international head-to-head trial of Aptivus®
- Details
- Category: Boehringer Ingelheim

Recommendation of Approval for the Merz Botulinum Neurotoxin Typ A in European Countries
- Details
- Category: Product
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) in London recommended the approval of the Merz- developed product Botulinum neurotoxin Type A. Merz is expecting approval in ten European countries within the next few months. The company already received approval in Denmark and Sweden.
The U.S. Launch of Neupro® for the Treatment of Early-Stage Parkinson's Disease
- Details
- Category: Product
UCB and SCHWARZ PHARMA announced today that Neupro® (Rotigotine Transdermal System), a new once-daily transdermal dopamine agonist approved for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, is now commercially available in retail pharmacies throughout the United States. Neupro® will be co-promoted by UCB and SCHWARZ PHARMA. These companies have dedicated sales forces that will immediately begin reaching out to physicians who treat Parkinson's disease nationwide.
Novartis Completes Divestment of Medical Nutrition Business
- Details
- Category: Novartis

Sandoz Receives Positive EU Opinion for Approval of epoetin alfa biosimilar
- Details
- Category: Novartis
Sandoz is the first company to receive a positive opinion from European Union regulators supporting the approval of a biosimilar version of epoetin alfa, achieving another important milestone in its efforts to bring follow-on biological medicines to patients.
More than 250,000 patients in Europe are estimated to be treated with epoetin alfa, which is marketed under various brand names, and similar medicines to regulate the formation of red blood cells. Worldwide annual sales are estimated at more than USD 7 billion, including USD 600 million in Europe.